全文获取类型
收费全文 | 15824篇 |
免费 | 1313篇 |
国内免费 | 163篇 |
专业分类
耳鼻咽喉 | 88篇 |
儿科学 | 386篇 |
妇产科学 | 194篇 |
基础医学 | 2103篇 |
口腔科学 | 308篇 |
临床医学 | 1617篇 |
内科学 | 3003篇 |
皮肤病学 | 144篇 |
神经病学 | 1497篇 |
特种医学 | 612篇 |
外科学 | 2101篇 |
综合类 | 389篇 |
一般理论 | 33篇 |
预防医学 | 1893篇 |
眼科学 | 293篇 |
药学 | 1172篇 |
中国医学 | 100篇 |
肿瘤学 | 1367篇 |
出版年
2023年 | 133篇 |
2022年 | 204篇 |
2021年 | 514篇 |
2020年 | 313篇 |
2019年 | 408篇 |
2018年 | 467篇 |
2017年 | 365篇 |
2016年 | 395篇 |
2015年 | 472篇 |
2014年 | 576篇 |
2013年 | 802篇 |
2012年 | 1228篇 |
2011年 | 1390篇 |
2010年 | 878篇 |
2009年 | 734篇 |
2008年 | 1103篇 |
2007年 | 1031篇 |
2006年 | 981篇 |
2005年 | 991篇 |
2004年 | 1051篇 |
2003年 | 896篇 |
2002年 | 695篇 |
2001年 | 183篇 |
2000年 | 138篇 |
1999年 | 120篇 |
1998年 | 143篇 |
1997年 | 113篇 |
1996年 | 97篇 |
1995年 | 66篇 |
1994年 | 68篇 |
1993年 | 57篇 |
1992年 | 76篇 |
1991年 | 46篇 |
1990年 | 43篇 |
1989年 | 37篇 |
1988年 | 33篇 |
1987年 | 42篇 |
1986年 | 38篇 |
1985年 | 33篇 |
1984年 | 31篇 |
1983年 | 26篇 |
1982年 | 27篇 |
1981年 | 23篇 |
1980年 | 16篇 |
1979年 | 22篇 |
1978年 | 21篇 |
1977年 | 18篇 |
1974年 | 14篇 |
1973年 | 13篇 |
1972年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
The group of Professor Ning Jiao and Professor Song Song have made new progress in the field of electrophilic halogenation modification of electron-deficient aromatics 下载免费PDF全文
5.
Thomas Asendorf Robin Henderson Heinz Schmidli Tim Friede 《Statistics in medicine》2019,38(9):1503-1528
In some diseases, such as multiple sclerosis, lesion counts obtained from magnetic resonance imaging (MRI) are used as markers of disease progression. This leads to longitudinal, and typically overdispersed, count data outcomes in clinical trials. Models for such data invariably include a number of nuisance parameters, which can be difficult to specify at the planning stage, leading to considerable uncertainty in sample size specification. Consequently, blinded sample size re-estimation procedures are used, allowing for an adjustment of the sample size within an ongoing trial by estimating relevant nuisance parameters at an interim point, without compromising trial integrity. To date, the methods available for re-estimation have required an assumption that the mean count is time-constant within patients. We propose a new modeling approach that maintains the advantages of established procedures but allows for general underlying and treatment-specific time trends in the mean response. A simulation study is conducted to assess the effectiveness of blinded sample size re-estimation methods over fixed designs. Sample sizes attained through blinded sample size re-estimation procedures are shown to maintain the desired study power without inflating the Type I error rate and the procedure is demonstrated on MRI data from a recent study in multiple sclerosis. 相似文献
6.
Aurora Perez-Cornago Georgina K. Fensom Colm Andrews Eleanor L. Watts Naomi E. Allen Richard M. Martin Mieke Van Hemelrijck Timothy J. Key Ruth C. Travis 《British journal of cancer》2020,123(12):1808
Background Although prostate cancer is a leading cause of cancer death, its aetiology is not well understood. We aimed to identify novel biochemical factors for prostate cancer incidence and mortality in UK Biobank.Methods A range of cardiovascular, bone, joint, diabetes, renal and liver-related biomarkers were measured in baseline blood samples collected from up to 211,754 men at recruitment and in a subsample 5 years later. Participants were followed-up via linkage to health administrative datasets to identify prostate cancer cases. Hazard ratios (HRs) and 95% confidence intervals were calculated using multivariable-adjusted Cox regression corrected for regression dilution bias. Multiple testing was accounted for by using a false discovery rate controlling procedure.Results After an average follow-up of 6.9 years, 5763 prostate cancer cases and 331 prostate cancer deaths were ascertained. Prostate cancer incidence was positively associated with circulating vitamin D, urea and phosphate concentrations and inversely associated with glucose, total protein and aspartate aminotransferase. Phosphate and cystatin-C were the only biomarkers positively and inversely, respectively, associated with risk in analyses excluding the first 4 years of follow-up. There was little evidence of associations with prostate cancer death.Conclusion We found novel associations of several biomarkers with prostate cancer incidence. Future research will examine associations by tumour characteristics.Subject terms: Predictive markers, Prostate cancer, Risk factors 相似文献
7.
8.
Julie A. Schmidt Georgina K. Fensom Sabina Rinaldi Augustin Scalbert Paul N. Appleby David Achaintre Audrey Gicquiau Marc J. Gunter Pietro Ferrari Rudolf Kaaks Tilman Kühn Heiner Boeing Antonia Trichopoulou Anna Karakatsani Eleni Peppa Domenico Palli Sabina Sieri Rosario Tumino Bas Bueno-de-Mesquita Antonio Agudo Maria-Jose Sánchez María-Dolores Chirlaque Eva Ardanaz Nerea Larrañaga Aurora Perez-Cornago Nada Assi Elio Riboli Konstantinos K. Tsilidis Timothy J. Key Ruth C. Travis 《International journal of cancer. Journal international du cancer》2020,146(3):720-730
Metabolomics may reveal novel insights into the etiology of prostate cancer, for which few risk factors are established. We investigated the association between patterns in baseline plasma metabolite profile and subsequent prostate cancer risk, using data from 3,057 matched case–control sets from the European Prospective Investigation into Cancer and Nutrition (EPIC). We measured 119 metabolite concentrations in plasma samples, collected on average 9.4 years before diagnosis, by mass spectrometry (AbsoluteIDQ p180 Kit, Biocrates Life Sciences AG). Metabolite patterns were identified using treelet transform, a statistical method for identification of groups of correlated metabolites. Associations of metabolite patterns with prostate cancer risk (OR1SD) were estimated by conditional logistic regression. Supplementary analyses were conducted for metabolite patterns derived using principal component analysis and for individual metabolites. Men with metabolite profiles characterized by higher concentrations of either phosphatidylcholines or hydroxysphingomyelins (OR1SD = 0.77, 95% confidence interval 0.66–0.89), acylcarnitines C18:1 and C18:2, glutamate, ornithine and taurine (OR1SD = 0.72, 0.57–0.90), or lysophosphatidylcholines (OR1SD = 0.81, 0.69–0.95) had lower risk of advanced stage prostate cancer at diagnosis, with no evidence of heterogeneity by follow-up time. Similar associations were observed for the two former patterns with aggressive disease risk (the more aggressive subset of advanced stage), while the latter pattern was inversely related to risk of prostate cancer death (OR1SD = 0.77, 0.61–0.96). No associations were observed for prostate cancer overall or less aggressive tumor subtypes. In conclusion, metabolite patterns may be related to lower risk of more aggressive prostate tumors and prostate cancer death, and might be relevant to etiology of advanced stage prostate cancer. 相似文献
9.
10.
Kate Ridley Tim S Olds Alison Hill 《The international journal of behavioral nutrition and physical activity》2006,3(1):10-11